Publication | Open Access
Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study
37
Citations
22
References
2023
Year
In children aged 6-11 years with moderate-to-severe type 2 asthma, dupilumab treatment was associated with rapid, sustained improvements in asthma control. HRQoL was significantly improved for children and their caregivers.
| Year | Citations | |
|---|---|---|
Page 1
Page 1